<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861793</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 4230-001</org_study_id>
    <nct_id>NCT03861793</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)</brief_title>
  <official_title>A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize the safety and tolerability and identify the recommended Phase 2
      dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with
      pembrolizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate ALKS 4230 administered SC as lead-in monotherapy and in combination
      with pembrolizumab in subjects with advanced solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs), and identify the RP2D of ALKS 4230 in Part A</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
    <description>Includes AEs that are both serious and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing AEs that are both serious and drug-related in Part B</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
    <description>Includes AEs that are both serious and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Activity of combination treatment with ALKS 4230 and pembrolizumab in each Part B tumor type.</measure>
    <time_frame>From time of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Overall Response rate (ORR) will be based on investigator review of radiographic and photographic images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with objective evidence of Complete Response (CR)/immune CR (iCR)</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Overall response rate (ORR) will be based on investigator review of radiographic or photographic images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with objective evidence of Partial Response (PR)/immune PR (iPR)</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>ORR will be based on investigator review of radiographic or photographic images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with CR/iCR</measure>
    <time_frame>Time from the first documentation of complete response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
    <description>CR/iCR duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with PR/iPR</measure>
    <time_frame>Time from the first documentation of complete response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
    <description>PR/iPR duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-progression for Part B</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Time from first dose of SC ALKS 4230 to the time of progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival for Part B</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Time from first dose of SC ALKS 4230 to the time of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ALKS 4230 will be determined at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Concentration vs time and standard pharmacokinetic (PK) parameters will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum will be assayed for the presence of anti-ALKS 4230 antibodies</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of proinflammatory cytokines will be assessed using a multiplex method at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">319</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ALKS 4230</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered via SC injection once every 7 days or once every 21 days at escalating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALKS 4230 will be administered via SC injection once every 21 days at escalating doses or at the recommended phase 2 dose; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALKS 4230</intervention_name>
    <description>SC injection administered in the back of the arm or the abdomen</description>
    <arm_group_label>ALKS 4230</arm_group_label>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered as an intravenous (IV) infusion over 30 minutes</description>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Part A the subject has histological or cytological evidence of a solid tumor. For
             Part B the subject must have 1 of the unspecified adult solid tumor types defined in
             the protocol

          -  Record of programmed cell death ligand 1 protein expression status, or availability of
             fresh or archival tumor tissue for cellular characterization and PD-L1 status

          -  Subjects must have adequate liver function

          -  Subjects must have adequate kidney function

          -  Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy,
             other prior systemic anticancer therapy, radiotherapy or surgery

          -  Subjects who have received radiation therapy must wait at least 4 weeks after their
             last radiation treatment before enrollment into the study

          -  Females of childbearing potential must have a negative pregnancy test within 7 days of
             the start of treatment and on Day 1 before the first dose is administered

          -  Subject will agree to follow contraceptive requirements defined in the protocol

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Subject is currently pregnant, planning to become pregnant, or breastfeeding

          -  Subjects with an active infection or with a fever ≥ 38.5°C within 3 days of the first
             scheduled day of dosing for Cycle 1

          -  Subjects with active or symptomatic central nervous system metastases are excluded.
             Subjects with central nervous system metastases are eligible for the study if the
             metastases have been treated by surgery and/or radiation therapy, the subject is off
             corticosteroids for at least 2 weeks, and the subject is neurologically stable

          -  Subjects with known hypersensitivity to any components of ALKS 4230 or to
             pembrolizumab or any of its excipients

          -  Subjects who require pharmacologic doses of steroids; replacement doses, topical,
             ophthalmologic, and inhalational steroids are permitted

          -  Subjects who developed autoimmune disorders while on prior immunotherapy, including
             pneumonitis, nephritis, and/or neuropathy

          -  Subjects with any other concurrent uncontrolled illness, including mental illness or
             substance abuse, which may interfere with the ability of the subjects to cooperate and
             participate in the study

          -  The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis
             B or C, or active tuberculosis, or has a known history of tuberculosis

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alkermes Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Owen</last_name>
    <phone>513-763-1937</phone>
    <email>Melanie.owen@syneoshealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkermes</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Oncology</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cytokine</keyword>
  <keyword>ALKS 4230</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time, IPD sharing has not been defined and/or decided if it will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

